A study to learn how safe ACT-777991 is and how well it works in adults with non-segmental vitiligo
EU CTIS ID: 2025-524865-25-00
What this study is testing
To assess the effect of ACT-777991, compared with placebo, on facial repigmentation in participants with non- segmental vitiligo.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Clinical diagnosis of either active or stable non-segmental vitiligo for at least 3 months prior to Screening and meet all the following criteria: – Facial Vitiligo Area Scoring Index (F-VASI) score ≥ 0.3 based on Blinded Independent Central Reading (BICR) at Screening. – Total Body Vitiligo Area Scoring Index (T-VASI) score ≥ 5 based on investigator assessment at Screening and Randomization. – Total body surface area (BSA) involvement, including the face, ≤ 50% based on investigator assessment at Screening and Randomization.
- Participants must not have discontinued, reduced, or modified a vitiligo treatment/procedure for the purpose of meeting trial eligibility criteria or a wash-out requirement. Participants must also agree not to use therapeutic agents and procedures to treat vitiligo from Screening until Patient Last Visit (PLV).
You likely can't join if
- Clinical diagnosis of other forms of vitiligo (e.g., segmental) or other hypo- or depigmentation disorders (e.g., piebaldism, leukoderma, Vogt-Koyanagi-Harada disease, malignancy-induced hypopigmentation).
- Any autoimmune disease, except adequately treated thyroid disease.
- History of systemic immunotherapy treatment, including JAK inhibitors, for any inflammatory disease in the 12 months prior to Randomization.
- History of topical JAK inhibitors for any inflammatory disease in the 6 weeks prior to Screening.
- Use of laser or light-based treatment (phototherapy), including tanning beds, in the 8 weeks prior to Screening.
- eGFR < 90 mL/min/1.73 m2, defined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation, at Screening.
The study team makes the final eligibility decision.
Where it's taking place
- Poland
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Poland; United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from EU CTIS. The study team decides eligibility, and your own doctor gives medical advice.